Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Shengnan Yu, Ming Yi, Shuang Qin, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 237

Showing 1-25 of 237 citing articles:

Notch signaling pathway: architecture, disease, and therapeutics
Binghan Zhou, Wanling Lin, Yaling Long, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 625
Combination strategies to maximize the benefits of cancer immunotherapy
Shaoming Zhu, Tian Zhang, Lei Zheng, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 430
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
Tobias Bald, Matthew F. Krummel, Mark J. Smyth, et al.
Nature Immunology (2020) Vol. 21, Iss. 8, pp. 835-847
Open Access | Times Cited: 370
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 248
Next-generation stem cells — ushering in a new era of cell-based therapies
Erin A. Kimbrel, Robert Lanza
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 7, pp. 463-479
Closed Access | Times Cited: 232
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials
Jason R. Westin, Marie José Kersten, Gilles Salles, et al.
American Journal of Hematology (2021) Vol. 96, Iss. 10, pp. 1295-1312
Open Access | Times Cited: 159
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets
Xiangyuan Luo, Kongming Wu, Xingxing He
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 152
Current Progress in CAR-T Cell Therapy for Hematological Malignancies
Donglei Han, Zenghui Xu, Yuan Zhuang, et al.
Journal of Cancer (2020) Vol. 12, Iss. 2, pp. 326-334
Open Access | Times Cited: 141
CAR-T: What Is Next?
Yi‐Ju Chen, Bams Abila, Yasser Mostafa Kamel
Cancers (2023) Vol. 15, Iss. 3, pp. 663-663
Open Access | Times Cited: 140
Advances in Universal CAR-T Cell Therapy
Haolong Lin, Jiali Cheng, Wei Mu, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 139
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
Nina Lamers-Kok, Denise Panella, Anna‐Maria Georgoudaki, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 97
Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma
Xiufeng Zheng, Xun Liu, Yanna Lei, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 83
CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application
Yu-Huan Yang, Jiawei Liu, Lü Chen, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 6, pp. 2609-2626
Open Access | Times Cited: 81
Adoptive T cell therapy for solid tumors: current landscape and future challenges
Víctor Albarrán, María San Román, Javier Pozas, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 21
CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
Yaxian Kong, Jingyao Li, Xia Zhao, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 3
Counteracting CAR T cell dysfunction
Mansour Poorebrahim, Jeroen Melief, Yago Pico de Coaña, et al.
Oncogene (2020) Vol. 40, Iss. 2, pp. 421-435
Open Access | Times Cited: 117
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Jianshu Wei, Yang Liu, Chunmeng Wang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 116
Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer
Sundee Dees, Rajkumar Ganesan, Sanjaya Singh, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 12, pp. 2409-2421
Open Access | Times Cited: 91
Engineering better chimeric antigen receptor T cells
Hao Zhang, Pu Zhao, He Huang
Experimental Hematology and Oncology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 84
Immunotherapy in Acute Myeloid Leukemia: Where We Stand
Alessandro Isidori, Claudio Cerchione, Naval Daver, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 84
Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives
Roman P. Labbé, Sandrine Vessillier, Qasim A. Rafiq
Viruses (2021) Vol. 13, Iss. 8, pp. 1528-1528
Open Access | Times Cited: 84
Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy
Renyu Zhang, Wei Ding, Ze-Kun Liu, et al.
Frontiers in Cell and Developmental Biology (2019) Vol. 7
Open Access | Times Cited: 81
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Runxia Gu, Fang Liu, Dehui Zou, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 71
Infectious complications of CAR T-cell therapy: a clinical update
Adam G. Stewart, Andrea S. Henden
Therapeutic Advances in Infectious Disease (2021) Vol. 8
Open Access | Times Cited: 70
Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
Lorenzo Lindo, Lauren Hanna Wilkinson, Kevin A. Hay
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 63
Page 1 - Next Page

Scroll to top